摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-(4-甲氧基苯基)-6-甲基-2-氧代-1H-吡啶-3-腈 | 84462-83-9

中文名称
5-(4-甲氧基苯基)-6-甲基-2-氧代-1H-吡啶-3-腈
中文别名
——
英文名称
5-(4-methoxy-phenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile
英文别名
1,2-dihydro-5-(4-methoxyphenyl)-6-methyl-2-oxonicotinonitrile;5-(4-Methoxyphenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile;5-(4-methoxyphenyl)-6-methyl-2-oxo-1H-pyridine-3-carbonitrile
5-(4-甲氧基苯基)-6-甲基-2-氧代-1H-吡啶-3-腈化学式
CAS
84462-83-9
化学式
C14H12N2O2
mdl
——
分子量
240.261
InChiKey
RHIYBCQHCZZWDU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    449.2±45.0 °C(Predicted)
  • 密度:
    1.24±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    18
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.14
  • 拓扑面积:
    62.1
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-(4-甲氧基苯基)-6-甲基-2-氧代-1H-吡啶-3-腈三溴化硼氯化铵 作用下, 以 二氯甲烷 为溶剂, 反应 7.0h, 以46%的产率得到5-(4-hydroxy-phenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carbonitrile
    参考文献:
    名称:
    [EN] DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY
    [FR] COMPOSES DE DIHYDROPYRIDINE PRESENTANT A LA FOIS LA CAPACITE DE BLOQUER DES CANAUX CALCIQUES DE TYPE L ET LA CAPACITE D'INHIBER L'ACTIVITE DE TYPE 3 DE LA PHOSPHODIESTERASE
    摘要:
    本发明提供了具有对PDE-3和L型钙通道具有抑制活性的化合物。本发明还提供了包含这些化合物的药物组合物以及使用这些化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法。
    公开号:
    WO2004033444A1
  • 作为产物:
    描述:
    4-dimethylamino-3-(4-methoxy-phenyl)-but-3-en-2-one氰乙酰胺甲醇 、 sodium hydride 作用下, 以 DMF (N,N-dimethyl-formamide) 为溶剂, 反应 18.25h, 生成 5-(4-甲氧基苯基)-6-甲基-2-氧代-1H-吡啶-3-腈
    参考文献:
    名称:
    [EN] DIHYDROPYRIDINE COMPOUNDS HAVING SIMULTANEOUS ABILITY TO BLOCK L-TYPE CALCIUM CHANNELS AND TO INHIBIT PHOSPHODIESTERASE TYPE 3 ACTIVITY
    [FR] COMPOSES DE DIHYDROPYRIDINE PRESENTANT A LA FOIS LA CAPACITE DE BLOQUER DES CANAUX CALCIQUES DE TYPE L ET LA CAPACITE D'INHIBER L'ACTIVITE DE TYPE 3 DE LA PHOSPHODIESTERASE
    摘要:
    本发明提供了具有对PDE-3和L型钙通道具有抑制活性的化合物。本发明还提供了包含这些化合物的药物组合物以及使用这些化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法。
    公开号:
    WO2004033444A1
点击查看最新优质反应信息

文献信息

  • 5-(Hydroxy- and/or amino-phenyl)-6-(lower-alkyl)-2-(1H)-pyridinones,
    申请人:Sterling Drug Inc.
    公开号:US04465686A1
    公开(公告)日:1984-08-14
    Disclosed and claimed is the cardiotonic use of 1-R.sub.1 -5-(3-R'-4-R"-phenyl)-6-R-2(1H)-pyridinones (II), where R.sub.1 is hydrogen, lower-alkyl or lower-hydroxyalkyl, R is lower-alkyl or hydrogen, and, R' and R" are each hydrogen, amino or hydroxy, at least one of R' or R" being other than hydrogen, or where R' is nitro when R" is hydroxy, or pharmaceutically acceptable acid-addition salts thereof where at least one of R' and R" is amino. Also disclosed and claimed are 1-R.sub.1 -5-(3-R'-4-R"-phenyl)-6-R-2(1H)-pyridinones (I), where R.sub.1, R' and R" are defined as above and R is lower-alkyl and acid-addition salts thereof where at least one of R' and R" is amino. Also shown and claimed is the process which comprises reacting 1-R.sub.1 -1,2-dihydro-2-oxo-5-(3-R'-4-R"-phenyl)-6-R-nicotinonitrile, where R.sub.1 and R are defined as above for II, R' is hydrogen, hydroxy, methoxy or amino and R" is hydroxy, methoxy or hydrogen, preferably at least one of R' and R" being methoxy, or where R' is nitro and R" is hydrogen or methoxy, preferably methoxy, with 85% phosphoric acid to produce 1-R.sub.1 -5-(3-R'-4-R"-phenyl)-6-R-2(1H)-pyridinone.
    揭示和声明了1-R.sub.1 -5-(3-R'-4-R"-苯基)-6-R-2(1H)-吡啶酮(II)的强心作用,其中R.sub.1为氢、低烷基或低羟基烷基,R为低烷基或氢,R'和R"分别为氢、氨基或羟基,其中至少有一个R'或R"不是氢,或者当R"为羟基时,R'为硝基,或其药学上可接受的酸加合物盐,其中至少一个R'和R"为氨基。还揭示和声明了1-R.sub.1 -5-(3-R'-4-R"-苯基)-6-R-2(1H)-吡啶酮(I),其中R.sub.1、R'和R"的定义如上所述,R为低烷基,以及其药学上可接受的酸加合物盐,其中至少一个R'和R"为氨基。还显示和声明了一种过程,包括将1-R.sub.1 -1,2-二氢-2-氧代-5-(3-R'-4-R"-苯基)-6-R-烟酸腈与85%磷酸反应,其中R.sub.1和R的定义如上所述用于II,R'为氢、羟基、甲氧基或氨基,R"为羟基、甲氧基或氢,最好是R'和R"中至少一个为甲氧基,或者当R'为硝基且R"为氢或甲氧基时,最好为甲氧基,以产生1-R.sub.1 -5-(3-R'-4-R"-苯基)-6-R-2(1H)-吡啶酮。
  • 3-Amino-5-(hydroxy- and/or
    申请人:Sterling Drug Inc.
    公开号:US04515797A1
    公开(公告)日:1985-05-07
    1-R.sub.1 -3-amino-5-(3-R'-4-R"-phenyl)-6-R-2(1H)-pyridinones or salts thereof, which are useful as cardiotonics, where R.sub.1 is hydrogen, lower-alkyl, or lower-hydroxyalkyl, R is hydrogen or lower-alkyl, and, R' and R" are each hydrogen, hydroxy or amino at least one of R' or R" being other than hydrogen, are prepared by reacting the corresponding 3-carbamyl compound with a reagent capable of converting carbamyl to amino or by first reacting the corresponding 3-carbamyl compound where R' and R" are each hydrogen, nitro or lower-alkoxy at least one of R' and R" being other than hydrogen with a reagent capable of converting carbamyl to amino and then reacting the resulting 3-amino compound where R' and/or R" are/is lower-alkoxy and/or nitro with a reagent capable of converting lower-alkoxy to hydroxy and/or with a reagent capable of converting nitro to amino. Preparation of the corresponding 3-carbamyl and 3-cyano compounds is shown, the latter including cardiotonically active novel 1-R.sub.1 -1,2-dihydro-5-(3-R.sub.2 -4-R.sub.3 -phenyl)-6-R-nicotinonitriles where R.sub.1 and R are defined as above, and R.sub.2 and R.sub.3 have the above given definitions for R' and R" or where R.sub.2 is nitro and R.sub.3 is hydroxy. Also shown are cardiotonic compositions and cardiotonic method of use of above-said compounds.
    1-R.sub.1 -3-氨基-5-(3-R'-4-R"-苯基)-6-R-2(1H)-吡啶酮或其盐,可用作心脏强心剂,其中R.sub.1是氢、低烷基或低羟基烷基,R是氢或低烷基,R'和R"分别是氢、羟基或氨基,其中R'或R"至少有一个不是氢,通过将相应的3-氨基甲酰化合物与能够将氨基甲酰转化为氨基的试剂反应制备,或者首先将R'和R"分别是氢、硝基或低烷氧基,其中R'和R"中至少有一个不是氢的相应的3-氨基甲酰化合物与能够将氨基甲酰转化为氨基的试剂反应,然后将所得的3-氨基化合物与能够将低烷氧基转化为羟基和/或能够将硝基转化为氨基的试剂反应,其中R'和/或R"是低烷氧基和/或硝基。显示了相应的3-氨基甲酰和3-氰基化合物的制备,后者包括具有心脏强心活性的新颖的1-R.sub.1 -1,2-二氢-5-(3-R.sub.2 -4-R.sub.3 -苯基)-6-R-烟酰腈,其中R.sub.1和R如上所定义,R.sub.2和R.sub.3具有上述给定的R'和R"的定义,或者其中R.sub.2是硝基,R.sub.3是羟基。还显示了心脏强心剂组合物和上述化合物的心脏强心方法的用途。
  • Compounds having simultaneous ability to block L-type calcium channels and to inhibit phosphodiesterase type 3 activity
    申请人:ARTESIAN THERAPEUTICS, INC.
    公开号:US20040242648A1
    公开(公告)日:2004-12-02
    The present invention provides compounds that possess inhibitory activity against PDE-3 and L-type calcium channels. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine.
    本发明提供了具有对PDE-3和L型钙通道的抑制活性的化合物。本发明还提供了包含这种化合物的药物组合物和使用这种化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法。
  • Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure
    申请人:Hamilton S. Gregory
    公开号:US20070060748A1
    公开(公告)日:2007-03-15
    This invention provides compounds that possess inhibitory activity against β-adrenergic receptors and phosphodiesterase PDE, including phosphodiesterase 3 (PDE3). This invention further provides pharmaceutical compositions comprising such compounds; methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine; and methods of preparing pharmaceutical compositions and compounds that possess inhibitory activity against β-adrenergic receptors and PDE.
    本发明提供了一种具有对β-肾上腺素能受体和磷酸二酯酶PDE,包括磷酸二酯酶3(PDE3)的抑制活性的化合物。本发明还提供了包含这些化合物的药物组合物;使用这些化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法;以及制备具有对β-肾上腺素能受体和PDE抑制活性的药物组合物和化合物的方法。
  • 3-Amino-5-(substituted)-2 (1H) pyridinones and 3-cyano compounds useful as cardiotonics and preparation thereof
    申请人:STERLING DRUG INC.
    公开号:EP0061774A2
    公开(公告)日:1982-10-06
    1-R1-3-amino-5-(3-R'-4-R"-phenyl)-6-R-2(1H)-pyridi- nones or salts thereof, which are useful as cardiotonics, where R, is hydrogen, lower-alkyl, or lower-hydroxyalkyl, R is hydrogen or lower-alkyl, and, R' and R" are each hydrogen, hydroxy or amino at least one of R' or R" being other than hydrogen, are prepared by reacting the corresponding 3-carbamyl compound with a reagent capable of converting carbamyl to amino or by first reacting the corresponding 3-carbamyl compound where R' and R" are each hydrogen, nitro or lower-alkoxy with a reagent capable of converting carbamyl to amino and then reacting the resulting 3-amino compound where R' and/or R" are/is lower-alkoxy and/or nitro with a reagent capable of converting lower-alkoxy to hydroxy and/or with a reagent capable of converting nitro to amino. Preparation of the corresponding 3-carbamyl and 3-cyano compounds are described. The invention also concerns the 3- and/or 4-methoxy intermediates and certain novel 3-cyano analogs. Cyano compounds are also useful as cardiotonics.
    1-R1-3-氨基-5-(3-R'-4-R"-苯基)-6-R-2(1H)-吡啶-壬烷或其盐,可用作强心剂,其中 R 是氢、低级烷基或低级羟基烷基,R 是氢或低级烷基,R'和 R "各自是氢、羟基或氨基,R'或 R "中至少有一个不是氢、将相应的 3-氨基甲酰基化合物与能将氨基甲酰基转化为氨基的试剂反应,或先将 R' 和 R "均为氢、硝基或低级烷氧基的相应 3-氨基甲酰基化合物与能将氨基甲酰基转化为氨基的试剂反应,然后将所得 R' 和/或 R "为/或低级烷氧基和/或硝基的 3-氨基化合物与能将低级烷氧基转化为羟基的试剂和/或能将硝基转化为氨基的试剂反应,制备 3-氨基甲酰基化合物。本发明描述了相应的 3-氨基甲酰基和 3-氰基化合物的制备方法。本发明还涉及 3-和/或 4-甲氧基中间体和某些新型 3-氰基类似物。氰基化合物还可用作强心剂。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-